Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Fulcrum Therapeutics, Inc. (FULC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 4 Musso Alan A (CFO) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 432,800 options to buy @ $4.01, valued at $1.7M
08/09/2023 3 Musso Alan A (CFO) has filed a Form 3 on Fulcrum Therapeutics, Inc.
07/03/2023 3 Sapir Alex (See Remarks) has filed a Form 3 on Fulcrum Therapeutics, Inc.
06/29/2023 4 GERAGHTY JAMES A (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $3.16, valued at $94.8k
06/29/2023 4 Haviland Kate (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $3.16, valued at $94.8k
06/29/2023 4 Dorton Katina (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $3.16, valued at $94.8k
06/29/2023 4 Banks Sonja (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $3.16, valued at $94.8k
06/29/2023 4 Ezekowitz Alan (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $3.16, valued at $94.8k
06/29/2023 4 Gould Robert J (Interim President & CEO) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $3.16, valued at $94.8k
06/29/2023 4 Collins James J. (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $3.16, valued at $94.8k
05/11/2023 4 Tourangeau Greg (Principal Accounting Officer) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Sold 210 shares @ $3.31, valued at $695.1
04/28/2023 4 Hayes Melvin H. III (COO) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 115,000 options to buy @ $2.58, valued at $296.7k
04/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/24/2023 4 RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Bought 1,923,076 shares @ $13, valued at $25M
01/13/2023 4 Gould Robert J (Interim President & CEO) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Sold 6,766 shares @ $15, valued at $101.5k
01/06/2023 4 RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Bought 122,334 shares @ $7.0276, valued at $859.7k
Bought 58,369 shares @ $7.7968, valued at $455.1k
12/29/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/15/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/09/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/09/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
08/26/2022 3 RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 3 on Fulcrum Therapeutics, Inc.
08/11/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/11/2022 4 Oltmans Curtis Gale (Chief Legal Officer) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 50,000 options to buy @ $7.4, valued at $370k
08/11/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
07/19/2022 4 Tourangeau Greg (Controller) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 16,540 options to buy @ $5.39, valued at $89.2k
06/29/2022 4 Ezekowitz Alan (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 19,000 options to buy @ $5.22, valued at $99.2k
Disposed of 500 options to buy @ $11.82, valued at $5.9k
06/29/2022 4 Haviland Kate (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns: Granted 19,000 options to buy @ $5.22, valued at $99.2k
06/29/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy